Aytu BioPharma, Inc.
NASDAQAytu BioPharma reported Q3 2026 results after the close on May 13, landing into an already-weakened stock — and the headline numbers tell a split story worth watching closely. The print itself was mixed. EPS came in at -$0.53, missing the -$0.51 consensus. Revenue of $12.4 million beat estimates of $12.1 million but continued to trend lower — down year-on-year, extending a pattern…
Snapshot as of 28 Jun 2026
Aytu BioPharma reported Q3 2026 results after the close on May 13, landing into an already-weakened stock — and the headline numbers tell a split story worth watching closely. The print itself was mixed. EPS came in at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AYTU — free to start on ORTEX.
Sign up for free →Open AYTU on ORTEX